1. Scrip
  2. >>New Products

Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease

 
• By Jessica Merrill

Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.

gray slate stone rock wall with breakthrough hole breakout freedom concept in front of green meadow with blue sky background - Image
A new drug is approved for sickle cell disease • Source: Shutterstock

Global Blood Therapeutics Inc. will be launching its first commercial drug, Oxbryta (voxelotor), for the treatment of sickle cell disease after securing FDA approval on 25 November. The drug will be available in two weeks, the company said.

Oxbryta is the second drug approved by the US Food and Drug Administration for sickle cell disease in just over one week, a landmark moment for the devastating blood disorder after years of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.